5 Most Promising Gene Editing Stocks According to Analysts

3. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Number of Hedge Fund Holders: 31

One-Year Average Price Target: $48.44

Biotechnology company Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a making a promising foray into the world of gene editing. Last year, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) entered into a partnership with gene editing company Metagenomi. The companies said that they will join hands to conduct research aimed initially at delivering investigational medicines for up to four genetic targets.

In December 2022, Morgan Stanley started covering Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) with an Equal Weight rating. Morgan Stanley said it expects a competitive launch for eplontersen in 2023 and that the treatment of the company will be the second drug to market for transthyretin amyloid polyneuropathy (ATTR-PN) after Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Amvuttra (patisiran).

In January, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) revealed that the FDA granted the Fast Track designation for its investigational therapy olezarsen for familial chylomicronemia syndrome (FCS), a rare form of dyslipidemia.